Skip to main content
VCbacked
Log inGet Started

Zucara Therapeutics

Vancouver, Canada

Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes.

$5.0M raised
May 2025
Series B
BiotechnologyDiabetesPharmaceutical

Top Investors

SanofiPerceptive AdvisorsBreakthrough T1DMitacsCanadian Glycomics Network

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Zucara Therapeutics

How much funding has Zucara Therapeutics raised?
Zucara Therapeutics has raised $5.0M in total funding. The most recent round was Series B. The last funding was announced in May 2025.
Who are Zucara Therapeutics's investors?
Zucara Therapeutics's investors include Sanofi, Perceptive Advisors, Breakthrough T1D, Mitacs, Canadian Glycomics Network.
Where is Zucara Therapeutics headquartered?
Zucara Therapeutics is headquartered in Vancouver, Canada.
What does Zucara Therapeutics do?
Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes.
What stage is Zucara Therapeutics at?
Zucara Therapeutics is at the Series B stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Zucara Therapeutics — Funding & Investors." VCBacked, May 1, 2025, https://www.vcbacked.co/company/zucara-therapeutics. Accessed June 4, 2026.
APA
VCBacked. (2025). Zucara Therapeutics — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/zucara-therapeutics
Wikipedia (cite web)
{{cite web |title=Zucara Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/zucara-therapeutics |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Virtuoso Surgical
Nashville
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Anagram Therapeutics
Boston
Prenetics
Hong Kong